SCHEDULE: Vigil Neuroscience Acquired by Sanofi

Vigil Neuroscience, Inc. has been acquired by Sanofi, with shareholders receiving $8.00 cash plus a $2.00 contingent value right per share.

Summary

• Vigil Neuroscience, Inc. (the "Issuer") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Sanofi and Vesper Acquisition Sub Inc. on May 21, 2025.
• The Issuer's stockholders voted to adopt the Merger Agreement at a special meeting on August 4, 2025.
• The merger closed on August 5, 2025, resulting in the Issuer becoming a wholly-owned subsidiary of Sanofi.
• Each outstanding share of Common Stock was converted into the right to receive $8.00 in cash, without interest.
• Additionally, each share received one contingent value right (CVR) representing the right to receive an additional $2.00 in cash, conditioned upon the satisfaction of a specific clinical milestone.
• The reporting persons (Atlas Venture entities) ceased to beneficially own any securities of Vigil Neuroscience as of the merger closing on August 5, 2025.

Sentiment

Score: 7

Explanation: The sentiment is positive for the reporting persons as they successfully exited their investment in Vigil Neuroscience through a merger, receiving a defined cash payment and a contingent value right, indicating a successful realization of their investment.

Positives

• Shareholders received a fixed cash payment of $8.00 per share upon the merger's closing.
• Shareholders are eligible for an additional $2.00 per share via a contingent value right, providing potential upside based on a clinical milestone.

Negatives

• The reporting persons, Atlas Venture entities, no longer hold any beneficial ownership in Vigil Neuroscience, indicating a full exit from their investment.

Risks

• The $2.00 per share contingent value right is subject to the satisfaction of a specific clinical milestone, meaning its payment is not guaranteed.

Future Outlook

The future outlook for former shareholders includes the potential to receive an additional $2.00 per share if a specified clinical milestone is achieved, as per the terms of the contingent value right.

Industry Context

This acquisition highlights ongoing consolidation and strategic M&A activity within the biotechnology and pharmaceutical sectors, particularly in the neuroscience therapeutic area, as larger pharmaceutical companies like Sanofi seek to expand their pipelines or acquire specialized assets.

Comparison to Industry Standards

• The filing does not provide specific details on comparable companies, projects, or results to assess the merger terms against broader industry standards. The valuation of $8.00 cash plus a $2.00 CVR per share would typically be evaluated against the target company's pre-merger market valuation, pipeline stage, and the perceived value of the contingent milestone.

Stakeholder Impact

• Shareholders of Vigil Neuroscience, Inc. received cash consideration and a contingent value right for their shares as a result of the merger.

Next Steps

• Monitoring the progress towards the clinical milestone that triggers the $2.00 per share contingent value right payment.

Key Dates

Keywords

Vigil Neuroscience, Sanofi, Merger, Acquisition, Biotechnology, Neuroscience, Contingent Value Right, CVR, Atlas Venture, SEC Filing, Schedule 13D/A